Received SEC

MAR 2 1 2017

Washington, DC 20549

William Slattery, CFA Vice President Listing Qualifications







17010336

By Electronic Mail

March 21, 2017

Mr. Jeffrey Thomas Chief, IT Services Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

Dear Mr. Thomas:

This is to certify that on March 21, 2017 The Nasdaq Stock Market (the "Exchange") received from Therapix Biosciences Ltd. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following security:

American Depositary Shares, each representing forty (40) Ordinary Shares, NIS 0.1 par value per share

We further certify that the security described above has been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

William Lattery